These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 8942890

  • 1. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.
    Camras CB, Alm A, Watson P, Stjernschantz J.
    Ophthalmology; 1996 Nov; 103(11):1916-24. PubMed ID: 8942890
    [Abstract] [Full Text] [Related]

  • 2. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group.
    Camras CB.
    Ophthalmology; 1996 Jan; 103(1):138-47. PubMed ID: 8628544
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.
    Alm A, Stjernschantz J.
    Ophthalmology; 1995 Dec; 102(12):1743-52. PubMed ID: 9098273
    [Abstract] [Full Text] [Related]

  • 7. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM, McGavin JK, Culy CR, Ibbotson T.
    Drugs Aging; 2003 Dec; 20(8):597-630. PubMed ID: 12795627
    [Abstract] [Full Text] [Related]

  • 8. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
    Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE.
    Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
    [Abstract] [Full Text] [Related]

  • 9. A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension.
    Friström B.
    Acta Ophthalmol Scand; 1996 Apr; 74(2):140-4. PubMed ID: 8739678
    [Abstract] [Full Text] [Related]

  • 10. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study.
    Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M.
    Arch Ophthalmol; 1996 Aug; 114(8):929-32. PubMed ID: 8694726
    [Abstract] [Full Text] [Related]

  • 11. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA, Travoprost Study Group.
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [Abstract] [Full Text] [Related]

  • 12. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.
    Watson PG.
    Ophthalmology; 1998 Jan; 105(1):82-7. PubMed ID: 9442782
    [Abstract] [Full Text] [Related]

  • 13. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA, Renard JP, Cunliffe IA, Rojanapongpun P.
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [Abstract] [Full Text] [Related]

  • 14. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension.
    Diestelhorst M, Larsson LI, European Latanoprost Fixed Combination Study Group.
    Br J Ophthalmol; 2004 Feb; 88(2):199-203. PubMed ID: 14736774
    [Abstract] [Full Text] [Related]

  • 15. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States.
    Alm A, Camras CB, Watson PG.
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S105-10. PubMed ID: 9154285
    [Abstract] [Full Text] [Related]

  • 16. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension.
    Zhang WY, Po AL, Dua HS, Azuara-Blanco A.
    Br J Ophthalmol; 2001 Aug; 85(8):983-90. PubMed ID: 11466259
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
    García Sanchez J.
    Eur J Ophthalmol; 2000 Aug; 10(3):198-204. PubMed ID: 11071026
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of latanoprost for glaucoma treatment: a three-month multicentric study in India.
    Thomas R, Parikh R, Sood D, Vijaya L, Sekhar GC, Sood NN, Baskaran M, Prasad KK, Latanoprost India Study Group.
    Indian J Ophthalmol; 2005 Mar; 53(1):23-30. PubMed ID: 15829743
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study.
    Aung T, Wong HT, Yip CC, Leong JY, Chan YH, Chew PT.
    Ophthalmology; 2000 Jun; 107(6):1178-83. PubMed ID: 10857840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.